Intesa Sanpaolo’s Neva SGR invests in nuclear fusion technology

Carlo Messina Managing Director and Chief Executive Officer of Intesa Sanpaolo Intesa Sanpaolo
Carlo Messina Managing Director and Chief Executive Officer of Intesa Sanpaolo - Intesa Sanpaolo
0Comments

Neva SGR, a venture capital company under the Intesa Sanpaolo Group, recently hosted an event at Officine Grandi Riparazioni in Turin. The gathering aimed to present the investment strategies of the Neva II and Neva II Italia funds, focusing on Climate Tech & Energy Transition. A key highlight was their investment in Commonwealth Fusion Systems (CFS), a notable player in nuclear fusion.

Luca Remmert, Chairman of Neva SGR, emphasized the company’s role in connecting Italian entrepreneurs with global venture capital networks. He stated, “Neva SGR connects Italian entrepreneurs with the global venture capital network and facilitates the entry of international entrepreneurs into the Italian scientific and industrial ecosystem, creating bridges that transform ideas into global opportunities.”

Bob Mumgaard, Co-founder and CEO of CFS, highlighted Italy’s potential economic benefits from fusion energy. He remarked, “In addition to access to clean, firm, almost limitless energy, fusion could be an opportunity of economic value especially for Italy because Italian companies are already an established part of the growing industry’s supply chain.”

The event also included discussions on sustainability led by key figures from Intesa Sanpaolo. Participants included Paola Angeletti, Tommaso Corcos, Gaetano Miccichè, and Jacques Moscianese.

Since its founding in 2020, Neva SGR has focused on investing in innovative companies addressing major global challenges across various sectors. In particular, they seek out companies with revolutionary patents that can contribute significantly to decarbonization efforts.

Neva SGR’s recent investment in CFS supports their development of SPARC—a tokamak-type reactor for magnetic confinement fusion—and aligns with their goal to facilitate collaboration between research institutions and Italy’s manufacturing sector.

Despite pandemic-related challenges since August 2020, Neva SGR has invested over 180 million euros through its initial funds. With new funds launched last September—Neva II and Neva II Italia—they have already invested approximately 24 million euros in two companies.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.